Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.24

-3.7%

12:01 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (20658)	7/27/2006 10:06:04 PM
From: Ian@SI	Read Replies (1) of 52153

But the analyst agrees with your assessment, if it works.. Renovis initiated with "sell" Thursday, July 27, 2006 3:56:26 AM ET Brean Murray, Carret & Co NEW YORK, July 27 (newratings.com) - Analyst Jonathan Aschoff of Brean Murray initiates coverage of Renovis Inc (RNVS.NAS) with a "sell" rating. The target price is set to $6. In a research note published yesterday, the analyst mentions that the SAINT II trial is unlikely to reach its primary endpoints. If Renovis' NXY-059 drug receives marketing approval and the company manages to gain 25% market share, the valuation of the drug would be around $14 per share, given its market potential, the analyst says. Renovis currently has no other drug in the development phase and the NXY-059 drug remains its biggest asset, Brean Murray adds

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next